Newsfeeds - Spark Newswire

1 minute read

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

Today, 10:05 AM

Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero Therapeutics shares rose 7.3% to $2.37 on Friday.

ACN

1 minute read

UnitedHealth To Rally 24%? Here Are 5 Other Price Target Changes For Thursday

By Lisa Levin

Today, 10:05 AM

Raymond James raised the price target on UnitedHealth Group Incorporated (NYSE: UNH) from $620 to $635. Raymond James analyst John Ransom maintained the stock with a Strong Buy rating. UnitedHealth shares rose 0.1% to $512.50 in pre-market trading.

1 minute read

RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $35

By Benzinga Newsdesk

Today, 10:05 AM

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $48 to $35.

1 minute read

Chemours, Alcoa And Other Big Losers From Wednesday

By Lisa Levin

Today, 10:05 AM

U.S. stocks closed lower with the Dow Jones dropping more than 500 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.

1 minute read

RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48

By Benzinga Newsdesk

Today, 10:05 AM

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $44 to $48.

2 minute read

Analyst Ratings

5 Analysts Have This to Say About Chemours

By Benzinga Insights

Today, 10:05 AM

Over the past 3 months, 5 analysts have published their opinion on Chemours (NYSE:CC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 minute read

UBS Maintains Neutral on Chemours, Raises Price Target to $37

By Benzinga Newsdesk

Today, 10:05 AM

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and raises the price target from $35 to $37.

3 minute read

The Dynamics Behind Carnival’s Q2 Earnings Rally

By Joel Elconin

Today, 10:05 AM

When an issue is in an extended downtrend and rallies off an earnings report, the next task is to determine if the rally will continue. That is what shareholders of Carnival Corp (NYSE: CC) were confronted with in Monday’s session.